Advertisement

Topics

Johnson Matthey Plc Company Profile

20:19 EST 13th December 2018 | BioPortfolio

Johnson Matthey is a speciality chemicals company and a world leader in advanced materials technology. The group focuses on its core skills in catalysts, precious metals and fine chemicals, developing products that enhance the quality of life for millions around the world.Since its foundation as a precious metals assayer in 1817, Johnson Matthey has continued to develop new technology, demonstrating its ability to maintain world leadership by adapting constantly to the ever-changing needs of customers. Today the company employs around 7,700 people in over 30 countries across the globe and its principal activities reflect its core skills.

Location

40-42 Hatton Garden
London
London
EC1N 8EE
United Kingdom

Contact

Phone: 44 (0)20 7269 8400
Fax: 44 (0)20 7269 8433
Email: webforms@magus.co.uk


News Articles [658 Associated News Articles listed on BioPortfolio]

Johnson Matthey expects a stronger second half

The company holds its AGM in London later this morning.2

Johnson & Johnson Posting Notable Loss But Well Off Lows

NEW BRUNSWICK (dpa-AFX) - Shares of Johnson & Johnson (JNJ) have climbed well off their worst levels of the day but remain in negative territory in late-day trading on Friday. Johnson & Johnson is...

Johnson Matthey offers new synthetic method for ‘ultra-pure’ CBD

The synthetic process produces a crystalline powder that can be particle size-adjusted for formulation requirements, says JM.

Liberum reckons the downgrades are over at Johnson Matthey (for the time being)

Analyst Adam Collins has moved the stock up to a ‘buy’, claiming that a growing share of the catalytic converter market in Europe should help to drive growth over the next couple of years

Johnson & Johnson verkauft Desinfektionssparte für 2,7 Milliarden Dollar: Johnson & Johnson steigt aus ...

Johnson & Johnson steigt aus dem Geschäft für Sterilisationsprodukte aus: Die Sparte übernimmt der Konzern Fortive für 2,7 Milliarden Dollar.Der Pharma- und Konsumgüterkonzern Johnson & Johnson (...

Johnson Matthey first-half profits rise 19%, full-year performance expected to be towards upper end of guidance

The FTSE 100-listed catalytic convertors maker saw its pre-tax profit increase by 19% to £244mln for the six months to 30 September, up from £205mln a year earlier

JM to offer a new process to synthesise CBD

Johnson Matthey to offer a new process to synthesise ultra-pure cannabidiol, expanding on existing cannabinoid offerings

Johnson & Johnson Vision: FDA Approves IDESIGN Refractive Studio - Quick Facts

Johnson & Johnson Vision, a unit of Johnson & Johnson (JNJ), said that the U.S. Food and Drug Administration (FDA) has approved of the iDESIGN Refractive Studio, making it the only system to use topog...

PubMed Articles [52 Associated PubMed Articles listed on BioPortfolio]

An Analysis of the FDA MAUDE Database and the Search for Cobalt Toxicity in Class 3 Johnson & Johnson/DePuy Metal-on-Metal Hip Implants.

This study was designed to determine whether systemic cobalt toxicity as an adverse event could be documented using the Food and Drug Administration's (FDA) Manufacturer and User Facility Device Exper...

Stevens-Johnson Syndrome: A Challenging Diagnosis.

Stevens-Johnson syndrome is a rare, yet life-threatening, delayed-type hypersensitivity reaction characterized by mucocutaneous epidermal necrolysis. Toxic epidermal necrolysis is a severe manifestati...

Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015).

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are serious mucocutaneous reactions. In Spain, the epidemiology and resulting expenses of these diseases are not well established.

Fluoxetine-induced Stevens-Johnson syndrome and liver injury.

Drug-induced liver injuries (DILI) are overall rare and often associated with use of medications. Medications are also the most common aetiology of Stevens-Johnson syndrome (SJS), but SJS is seldom se...

Corneal limbal stem cell deficiency in children with Stevens-Johnson syndrome.

To determine the incidence of corneal limbal stem cell deficiency (LSCD) as chronic ocular sequelae in children with Stevens-Johnson syndrome (SJS) / toxic epidermal necrolysis (TEN) and analyze the f...

Clinical Trials [53 Associated Clinical Trials listed on BioPortfolio]

Stevens-Johnson Syndrome Antimicrobial

Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacteri...

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion crit...

Extracorporeal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allow...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition

The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 ...

Companies [168 Associated Companies listed on BioPortfolio]

Macfarlan Smith

Founded in 1780, Macfarlan Smith has over 200 years of expertise in natural product extractions and chemical synthesis, specialising in opiate narcotics such as Codeine and Morphine. Over the past 2 c...

Aoxing Pharmaceutical Company

Johnson Matthey is a specialty chemicals company, publicly traded in London Stock Exchange, focused on its core skills in catalysis, precious metals, fine chemicals and process technology. Johnson Ma...

Johnson Matthey Plc

Johnson Matthey is a speciality chemicals company and a world leader in advanced materials technology. The group focuses on its core skills in catalysts, precious metals and fine chemicals, developing...

Johnson Matthey Pharma Services

We are a pharmaceutical chemistry services company providing API outsourcing solutions throughout the drug development process, from early stage discovery services to commercial manufacturing.We enabl...

Johnson and Johnson

Johnson & Johnson, employing approximately 119,000 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnso...

More Information about "Johnson Matthey Plc" on BioPortfolio

We have published hundreds of Johnson Matthey Plc news stories on BioPortfolio along with dozens of Johnson Matthey Plc Clinical Trials and PubMed Articles about Johnson Matthey Plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Johnson Matthey Plc Companies in our database. You can also find out about relevant Johnson Matthey Plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record